Decline in physical function with age Not Applicable Physical function
Conditions
Interventions
Spironolactone 25 mg once daily or placebo once daily for a period of 20 weeks.
Sponsors
University of Dundee (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged 65 years and over, either sex 2. Self-reported problems with activities of daily living
Exclusion criteria
Exclusion criteria: 1. A clinical diagnosis of symptomatic heart failure according to the Economic and Social Research Council (ESRC) criteria 2. Asymptomatic left ventricular systolic dysfunction 3. Already taking spironolactone 4. On angiotensin converting enzyme inhibitor or angiotensin receptor blocker 5. Systolic blood pressure less than 100 mmHg 6. Serum potassium greater than 5.0 mmol/l 7. Serum sodium less than 130 mmol/l 8. Creatinine greater than 200 umol/l 9. Estimated glomerular filtration rate (eGFR) less than 30 ml 10. Addison's disease 11. Previous reported intolerance of spironolactone 12. Cognitive impairment precluding informed consent 13. Wheelchair bound 14. Unwilling to participate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in six minute walking distance over 20 weeks from baseline | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in the following from baseline to 20 weeks: 1. Time taken to perform the timed get up and go test 2. EuroQol 5D (-0.59 to 1.0) and Visual Analogue Scale (0 - 100) 3. Functional Limitation Profile Scale 4. Hospital Anxiety and Depression Scale (anxiety 0 - 21; depression 0 - 21) 5. Incremental shuttle walk test (time and distance) | — |
Countries
United Kingdom
Outcome results
None listed